Combinations of EGFR-TKIs and other types of agents have been investigated in the first-line setting, such as antiangiogenic agents (bevacizumab and ramucirumab) combined with erlotinib.

EGFR-TKI 与其他类型药物的组合已在一线环境中进行了研究，血药物（贝伐珠和雷莫芦）与厄洛替尼的组合。

34-36 A concern for patients with BM treated with antiangiogenic therapies has been intracranial hemorrhage (ICH).

34-36 对于接受血疗法治疗的 BM 患者来说，一个令人担忧的问题是颅内出血 (ICH)。

Antiangiogenic agents have shown modest additional benefits when added to chemotherapy in both the first- and second-line settings, including in patients with BM.

在一线和二线治疗中（包括 BM 患者）将血药物添加到化疗中时，已显示出适度的额外益处。